Pancreatic Cancer Research

ResearcherNational Cheng Kung University HospitalActive in the last 2 years

Ya‐Chin Hou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9918-9568; OpenAlex author ID A5021060039. Sources: OpenAlex.

Their work

Papers
21 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 3 papers

Papers 21

  1. TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling. Co-author DOI 10.1007/s13402-026-01203-8↗
  2. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC. Co-author DOI 10.1158/1078-0432.ccr-25-4564↗
  3. Stromal CCL2/CXCL10/SPARC axes drive pro-tumor CHI3L1 expression for microenvironmental modulation in pancreatic cancer progression and therapeutic innovation. Co-author DOI 10.1186/s12929-026-01295-2↗
  4. Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. First author DOI 10.1002/ctm2.70394↗
  5. Macrophage activation determines muscle wasting in pancreatic cancer. Co-author DOI 10.1038/s41388-025-03434-9↗
  6. Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells. First author DOI 10.1186/s12943-024-02207-4↗
  7. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis. Co-author DOI 10.1002/advs.202306373↗
  8. Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment. Co-author DOI 10.1158/1535-7163.mct-23-0767↗
  9. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Co-author DOI 10.1038/s41467-023-42402-3↗
  10. New insights into the role of adipocytes in pancreatic cancer progression: paving the way towards novel therapeutic targets. First author DOI 10.7150/thno.82911↗
  11. Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination. First author PMID 37693128↗
  12. RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02325-7↗
  13. The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers14133137↗
  14. Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway. Co-author DOI 10.3390/ijms23052608↗
  15. Epigenetic silencing of AATK in acinar to ductal metaplasia in murine model of pancreatic cancer. First author DOI 10.1186/s13148-020-00878-6↗
  16. The differential distributions of ASPM isoforms and their roles in Wnt signaling, cell cycle progression, and pancreatic cancer prognosis. Co-author DOI 10.1002/path.5341↗
  17. Low CD8⁺ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44⁺/CD133⁺ Cancer Stem Cells and Predict an Unfavorable Prognosis in Panc… Co-author DOI 10.3390/cancers11040541↗
  18. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Co-author DOI 10.7150/thno.36830↗
  19. Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes. Co-author DOI 10.3390/jcm7120502↗
  20. Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine. Co-author DOI 10.1186/s12943-015-0449-3↗
  21. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal … Co-author DOI 10.1002/cncr.28774↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan‐Shen Shan · 20 shared papers, 2014–2026 · strength 3.32
  2. Hao‐Chen Wang · 10 shared papers, 2014–2026 · strength 1.48
  3. Ying‐Jui Chao · 7 shared papers, 2014–2026 · strength 1.05
  4. Li‐Tzong Chen · 5 shared papers, 2019–2026 · strength 1.01
  5. Yung‐Yeh Su · 4 shared papers, 2022–2026 · strength 0.81
  6. Wen‐Chun Hung · 3 shared papers, 2022–2025 · strength 0.68
  7. Yi‐Ching Wang · 3 shared papers, 2020–2026 · strength 0.64
  8. Pei-Chia Su · 2 shared papers, 2025–2026 · strength 0.56
  9. Po-Hsien Huang · 4 shared papers, 2019–2025 · strength 0.51
  10. Siao Muk Cheng · 2 shared papers, 2025–2026 · strength 0.46
  11. Li-Yun Ding · 3 shared papers, 2020–2025 · strength 0.42
  12. Nai‐Jung Chiang · 2 shared papers, 2022–2026 · strength 0.39
  13. Yan-Shen Shan · 1 shared paper, 2026 · strength 0.36
  14. Yu‐Hsuan Hung · 2 shared papers, 2022–2023 · strength 0.35
  15. Szu-Ying Chen · 2 shared papers, 2022–2025 · strength 0.33
  16. Chih‐Han Chang · 2 shared papers, 2022–2025 · strength 0.33
  17. Tzu‐Lei Kuo · 1 shared paper, 2025 · strength 0.33
  18. Hong Li · 2 shared papers, 2023–2024 · strength 0.27
  19. Chi‐Ling Chiang · 2 shared papers, 2023–2024 · strength 0.27
  20. L. James Lee · 2 shared papers, 2023–2024 · strength 0.27
  21. Yu‐Chun Lin · 1 shared paper, 2023 · strength 0.26
  22. Chang-Jung Chen · 1 shared paper, 2024 · strength 0.26
  23. Chia‐Ming Yeh · 1 shared paper, 2026 · strength 0.24
  24. Hui‐Jen Tsai · 1 shared paper, 2026 · strength 0.24
  25. Chuan Wang · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.